Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-blind, Active-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Co-administrated Ezetimibe/Rosuvastatin and Telmisartan in Patients With Essential Hypertension and Primary Hypercholesterolemia

NCT04659070 is registered in ClinicalTrials.gov with Hanlim Pharm. Co., Ltd. as lead sponsor.

NCT NCT04659070
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04659070 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-blind, Active-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Co-administrated Ezetimibe/Rosuvastatin and Telmisartan in Patients With Essential Hypertension and Primary Hypercholesterolemia
Lead sponsor
Hanlim Pharm. Co., Ltd.
Phase
Phase 3
Overall status
Unknown status
Start date
July 15, 2020
Completion date
May 19, 2022
Enrollment
156 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hypertension, primary hypercholesterolemia